AMGEN Inc.

This committee provides the official revenue estimates and technical analysis for all tax legislation, which directly influences corporate tax structures, capital investment incentives, and Amgen's overall tax burden and financial strategy.

This is a critical committee for Amgen, controlling taxation, trade, and entitlement spending like Medicare and Medicaid. Its decisions on drug pricing and reimbursement policies for these programs directly impact Amgen's revenue and profitability.

This committee determines the precise allocation of federal spending, including funding for the NIH, FDA, and major healthcare programs (e.g., Medicare/Medicaid purchasing), directly impacting Amgen's R&D environment and customer base.

This committee directly regulates the FDA, which is critical for drug approval, and oversees NIH funding, which impacts research. These are central to Amgen's discovery, development, and market access.

Intellectual property (patents) is foundational to the biotechnology industry. This committee's oversight of antitrust laws and intellectual property directly impacts Amgen's core business model, R&D protection, and potential M&A activities.